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TNM stage T1-2, N0, M0 with PSA 10 ng/Ml and Gleason
score 7, and localized PC as TNM stage T2, N0, M0. Next, we
developed models for estimating the number of men in these two
groups for the US, European Union (EU) and Japan. Finally, we
populated these models with information derived from a com-
prehensive review of incidence and staging estimates from
English-language literature and publicly available demographic
and registry data. RESULTS: We identiﬁed over 100 relevant
abstracts that yielded 67 manuscripts for review, 15 of which
provided data for the model. The estimated number of newly
diagnosed men with early-stage PC was 120,000 (US), 140,000
(EU), and 4,300 (Japan). The corresponding incidence rates per
100,000 males were 85, 58 and 7, respectively. The estimated
number (incidence) of newly diagnosed men with localized PC
was 89,000 (63), 71,000 (29) and 10,000 (15) in the US, EU and
Japan, respectively. CONCLUSION: The number of men at risk
for over- or under-utilization of radical prostatectomy due to
inadequate diagnostic information is substantial and varies
widely by country.
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OBJECTIVES: Although the use of various generic drugs is
becoming national policy in Japan to reduce health care costs,
many physicians tend to be reluctant to prescribe generic drugs,
especially in cancer therapy. The purpose of this study was to
investigate the attitude of physicians involved in breast cancer
treatment towards the prescription and use of generic anti-cancer
drugs in Japan. METHODS: Questionnaires were sent to 180
physicians who had registered with the multi-center trial group
for breast cancer therapy in Japan (CSPOR). RESULTS: The
respondents were 73 (response rate: 41%), their average age was
45.1, and their years of experience with breast cancer treatment
averaged 14.1. Their basic attitude concerning generic drugs was
“I would prescribe them if the patient asks” among 64%, “I am
actively prescribing them” among 21%, and “I would prefer not
to prescribe them, if possible” among 14% of respondents. 32%
of physicians had no experience with the use of generic anti-
cancer drugs. The reasons why they did not use them were
“constraints of the ordering system” (49%), “my own policy”
(21%), and “institutional policy” (13%). The policy for the
selection of brand or generic anti-cancer drugs was “based on
patients’ preference” (44%), “commitment to generic drugs”
(14%), “decide by the name of the drug company” (24%), and
“follow the institutional policy” (24%). As to the selection of
generic drugs, seventy-nine percent of respondents trusted
generic drugs manufactured by a brand name company over
those made by a specialized producer of generic drugs. CON-
CLUSION: A little less than 70 percent of breast cancer thera-
pists had prescribed generic anti-cancer drugs. It became clear
that the selection policy for brand or generic anti-cancer drugs
was based on patient preferences.
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OBJECTIVES: During the last decades, breast cancer screening
programs have considerably increased in terms of number and
improved in terms of clinical and technical standards. From an
HTA perspective, clinical and economic issues are only two of
several important aspects concerning breast cancer screening
programs. The objective of research is to investigate to what
extend societal and ethical aspects as well as the perspective of
equal access for different groups of the population are addressed
in breast cancer screening evaluation initiatives. METHODS:
Systematic literature research; comparative analysis of societal,
ethical and access aspects on the basis of several practical
examples of screening programs in different countries and of
theoretic scientiﬁc literature; evaluating structures of program-
organisation along pre-deﬁned indicators. RESULTS: In several
countries breast cancer screening programs are also evaluated
according to others than conventional indicators. These indica-
tors do express attendance rates according to different social
groups, and thus may explain differences in epidemiological out-
comes of screening programs. CONCLUSION: Basic epidemio-
logical indicators of the success of breast cancer screening such as
prevalence can strongly vary depending on non-clinical and non-
economic characteristics of screening programs. These societal,
ethnic, ethical or equity aspects are primarily to be addressed via
the organisational part of the programs. This is one reason why
quality assurance in breast cancer screening should not only be
strictly executed but also be improved in terms of a quality
management.
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OBJECTIVES: Describe the treatment patterns of GBM patients
in Germany. METHODS: Between January and February 2006,
retrospective case histories of 50 adult GBM patients no longer
receiving active treatment were provided by 10 physicians from
10 German institutions. RESULTS: Seventy percent of patients
were diagnosed in 2004–5. 60% of patients were male; 58%
were >50 years old. At diagnosis, patients were classed as fully
active (26% with no neurological symptoms; 42% with minor
symptoms); 22% were fully active with assistance with moderate
symptoms, 6% were less than fully active with moderate symp-
toms and 4% were disabled with severe symptoms. 49 patients
had their initial therapy recorded; all underwent surgery. Subse-
quently, 39% underwent chemoradiation, 39% radiotherapy,
and 14% chemotherapy. Of those undergoing chemoradiation,
94% received temozolomide. Of those undergoing radiotherapy,
53% subsequently received chemotherapy before relapse; 90%
received temozolomide either as a single-agent or in combination
with doxorubicin. Disease recurrence was documented for 36 of
50 patients, of which 13% had no neurological symptoms, 41%
had minor symptoms, 28% had moderate symptoms and were
fully active with assistance, and 19% had moderate symptoms
and were less than fully active. Forty-two percent (15/36) were
treated with chemotherapy initially for their recurrence; patients
received a variety of single-agent or combination regimens of
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which temozolomide, nimustine, doxorubicin, and teniposide
were most common. 53% of these patients received subsequent
chemotherapy regimens.forty-four percent (16/36) underwent
surgery initially for their recurrence, with 81% (13/16) of these
patients receiving subsequent chemotherapy. Other drugs used in
treatment of recurrent disease included doxorubicin and lomus-
tine. CONCLUSION: Consistent with published guidelines,
GBM patients in Germany with better functional status undergo
active therapy. Patients initially undergo surgery, followed by
radiotherapy. Chemotherapy is often used with or immediately
following radiotherapy or at disease recurrence.
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OBJECTIVES: This oncology-speciﬁc organization integrated
into its electronic medical record (EMR) system a series of clini-
cal pathways (CPs) based on national guidelines. The objective
was to to evaluate adherence to pathways and develop a pro-
cess for communication to practices regarding performance.
METHODS: The CPs are based on clinical and economic litera-
ture and are physician-led. Adherence is measured using a com-
bination of patient disease, stage of disease, and line of therapy.
A combination of methods has been used in the reporting
process, including web-based reports; involvement of staff phar-
macists to promote and monitor clinical pathway adherence at
the local level; multiple teleconferences among pharmacists and
physicians to discuss cases, share successes, failures, and ideas;
and inclusion of network pathway reports for all attendees at the
organization’s biannual national P&T meetings. RESULTS:
Eighteen practices have EMR pathway reporting capabilities,
with new practices being added every month. Currently clinical
pathways for 7 cancer types have been implemented into the
EMR system. Pharmacists have increased their role in promoting
pathway adherence. One of the greater challenges has not been to
improve pathway adherence per se, but to increase completion
of key elements of evaluation, including disease stage and line of
therapy. CONCLUSION: Early evaluation shows monitoring of
pathways can be conducted with use of an EMR. Regular feed-
back on missing data has encouraged providers to update clinical
data entry. The complexity and dynamic nature of oncology
treatment requires frequent evaluation of clinical pathways to
ensure they are current and are based on both clinical and
economic evidence.
CANCER—Methods and Concepts
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OBJECTIVES: Conventional cost-effectiveness analysis are
usually supported by clinical data collected in phase III RCTs
(Drummond, 2005) and it is typically based on time-to-event
data. However, ignoring mean quality-adjusted survival for mul-
tiple transitions may introduce some estimates bias. Multi-state
models appeared to eliminate some limitations of Q-TWiST
models such as the necessity for progressive states (Billingham,
1999), but the applicability of these models in heath economics is
still unclear. The aim of this analysis is to compare the results of
two modeling alternatives: conventional cost-effectiveness analy-
sis and multi-state cost-effectiveness analysis taking capecitabine
versus docetaxel in mBC in Brazil as a study case. METHODS:
Conventional and multi-state survival analysis techniques were
applied on O’Shaugnessy (2001) data to perform both cost-
effectiveness analysis. For the conventional survival analysis, a
Cox and parametric approach were used, and the best ﬁt was
chosen analyzing Cox-Snell and deviance residuals, as well as
AIC and BIC criteria. For multi-state survival analysis, the model
estimation was based on Gardiner (2006), and assumed as a
three-stage non-homogeneous Markov process. For costs, the
resource use was obtained from O’Shaugnessy trial and unit costs
were derived from published lists such as CBHPM 2004, Simpro
magazine and PROAHSA report. RESULTS: In conventional
analysis the incremental cost-effectiveness ratio (ICER) was
R$26,208 per QALY assuming log-logistic distributions which
was the best ﬁtted one, meanwhile in multi-state analysis, the
incremental cost-effectiveness ratio was R$19,320 per QALY
using weilbull distributions (Klein, 1994). PSA was performed
using Monte-Carlo simulations that supported the robustness
of the ﬁndings. CONCLUSION: Despite multi-state analysis
demands more sophisticated statistical background, there is an
evident superiority in multi-state estimates precision and accu-
racy when performing cost-effectiveness analysis. Regarding to
capecitabine, it was observed that in both models its addition in
this setting could be considered as a cost-effective alternative
under the private payer perspective in Brazil.
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OBJECTIVES: To investigate the impact of chronic lymphocytic
leukaemia (CLL) on health-related quality of life (HRQL) and
the gain in terms of descriptive richness associated with using an
EQ-5D with additional levels (EQ-5D-5L) in the CLL patient
population. METHODS: The EQ-5D-5L employed in this study
incorporates 5 levels of assessment but without additional label-
ling (Levels 2 and 4 are unlabeled). Our study involves a cohort
of patients with CLL from 19 participating Dutch centres.
Health-related quality of life (HRQL) is assessed at 6 monthly
intervals. The following analysis is based on the initial HRQL
assessment, which captured patients at various phases in their
disease course. RESULTS: In March 2006, 134 patients had
completed at least one EQ-5D-5L questionnaire of whom 63%
were male of median age 66 years. Median age for females was
higher at 70 years. Most patients (72%) were in remission at the
time of the ﬁrst HRQL assessment. Twenty-six percent selected at
least one alternative level on the EQ-5D-5L. The dimensions
where patients reported most problems were Pain/Discomfort
(level 1: 57%, level 2: 8%, level 3: 32%, level 4: 1%) and Usual
Activities (level 1: 62%, level 2: 7%, level 3: 28%, level 4: 2%,
level 5: 1%), followed by the Mobility dimension (level 1: 69%,
level 2: 8%, level 3: 22%). Few patients reported problems in
terms of Self-care (5%). The mean VAS score was 75.08
(SD = 14.3). Utility scores were 0.88 (SD = 0.15) for the EQ-5D-
5L, slightly higher than for the 3-level categorization at 0.84
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